Production and Preparation

PP-003

RISK MATRIX FOR STERILE COMPOUNDED PRODUCTS: DESIGN AND VALIDATION

PP-002

COMPOUNDING FOR PAEDIATRIC PATIENTSINCREASING QUALITY THROUGH MECHANISATION?

PP-036

PREPARATION OF AN EXPERIMENTAL CORD BLOOD SERUM EYE DROPS FOR TOPICAL USE IN SEVERE CORNEAL EPITHELIOPATHY

PP-002

COMPATIBILITY AND STABILITY OF HYOSCINE N-BUTYL BROMIDE AND FUROSEMIDE ADMIXTURES FOR USE IN PALLIATIVE CARE

PP-035

ALBUMIN DESENSITIZATION

PP-034

ENVIRONMENTAL CONTAMINATION WITH CYTOTOXIC DRUGS IN A RECONSTITUTION UNIT

PP-033

NYSTATIN-LIDOCAINE LOZENGES: INNOVATION IN THE TREATMENT OF ORAL MUCOSITIS

PP-032

CLOTTING CONTROL IN A HAEMODIALYSED PATIENT WITH ALLERGIC TO LOW MOLECULAR WEIGHT HEPARIN (LMWH).

PP-031

THE USE OF GUIDELINES IN THE CYTOTOXIC DRUGS PREPARATION UNIT: WHAT IS THE REAL WORKLOAD FOR PHARMACY TECHNICIANS?

PP-030

100.000 TREATMENTS PREPARED BY ROBOT: WHAT HAVE WE LEARNED?

PP-029

NON-COMEDOGENIC FORMULATION OF TOPICAL SIROLIMUS FOR TUBEROUS SCLEROSIS PATIENTS WITH FACIAL ANGIOFIBROMAS DEVELOPING ACNE COSMETICA

PP-028

LONG-TERM STABILITY OF DILUTED SOLUTIONS OF THE MONOCLONAL ANTIBODY INFLIXIMAB

PP-027

LONG-TERM STABILITY OF SOLUTIONS OF THE MONOCLONAL ANTIBODY CETUXIMAB

PP-026

EVALUATION OF LONG-TERM BIOLOGICAL ACTIVITY OF TRASTUZUMAB 15.0 mg /mL(Herceptin) BY AN AD HOC ELISA METHOD

PP-025

STABILITY OF INTRAVITREAL BEVACIZUMAB SOLUTION IN POLYPROPYLENE SYRINGES IN NEOVASCULAR MACULAR DEGENERATION

Pages